| AKT activation predicts outcome in breast cancer patients treated with tamoxifen T Kirkegaard, CJ Witton, LM McGlynn, SM Tovey, B Dunne, A Lyon, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2005 | 340 | 2005 |
| Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation L Kjøller, SM Kanse, T Kirkegaard, KW Rodenburg, E Rønne, ... Experimental cell research 232 (2), 420-429, 1997 | 306 | 1997 |
| Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial PJ Devereaux, E Duceppe, G Guyatt, V Tandon, R Rodseth, BM Biccard, ... The Lancet 391 (10137), 2325-2334, 2018 | 295 | 2018 |
| Proteinases in bone resorption: obvious and less obvious roles JM Delaissé, MT Engsig, V Everts, M del Carmen Ovejero, M Ferreras, ... Clinica Chimica Acta 291 (2), 223-234, 2000 | 285 | 2000 |
| Tumour necrosis factor α converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease J Brynskov, P Foegh, G Pedersen, C Ellervik, T Kirkegaard, A Bingham, ... Gut 51 (1), 37-43, 2002 | 267 | 2002 |
| Tumour necrosis factor α converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease J Brynskov, P Foegh, G Pedersen, C Ellervik, T Kirkegaard, A Bingham, ... Gut 51 (1), 37-43, 2002 | 267 | 2002 |
| Observer variation in immunohistochemical analysis of protein expression, time for a change? T Kirkegaard, J Edwards, S Tovey, LM McGlynn, SN Krishna, ... Histopathology 48 (7), 787-794, 2006 | 264 | 2006 |
| Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn’s disease T Kirkegaard, A Hansen, E Bruun, J Brynskov Gut 53 (5), 701-709, 2004 | 259 | 2004 |
| A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells TL Andersen, M del Carmen Ovejero, T Kirkegaard, T Lenhard, NT Foged, ... Bone 35 (5), 1107-1119, 2004 | 192 | 2004 |
| Transforming growth factor-β controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression MA Karsdal, P Hjorth, K Henriksen, T Kirkegaard, KL Nielsen, H Lou, ... Journal of Biological Chemistry 278 (45), 44975-44987, 2003 | 181 | 2003 |
| Amplified in breast cancer 1 in human epidermal growth factor receptor–positive tumors of tamoxifen-treated breast cancer patients T Kirkegaard, LM McGlynn, FM Campbell, S Müller, SM Tovey, B Dunne, ... Clinical cancer research 13 (5), 1405-1411, 2007 | 142 | 2007 |
| Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption P Hou, T Troen, MC Ovejero, T Kirkegaard, TL Andersen, I Byrjalsen, ... Bone 34 (1), 37-47, 2004 | 131 | 2004 |
| Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients LM McGlynn, T Kirkegaard, J Edwards, S Tovey, D Cameron, C Twelves, ... Clinical cancer research 15 (4), 1487-1495, 2009 | 114 | 2009 |
| Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium G Pedersen, T Saermark, T Kirkegaard, J Brynskov Clinical & Experimental Immunology 155 (2), 257-265, 2009 | 76 | 2009 |
| Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH T Kirkegaard, CJ Witton, J Edwards, KV Nielsen, LB Jensen, ... Histopathology 56 (2), 203-211, 2010 | 70 | 2010 |
| High CDK6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor–positive metastatic breast cancer CL Alves, D Elias, M Lyng, M Bak, T Kirkegaard, AE Lykkesfeldt, HJ Ditzel Clinical cancer research 22 (22), 5514-5526, 2016 | 66 | 2016 |
| Kinetic analysis of integrin‐dependent cell adhesion on vitronectin: The inhibitory potential of plasminogen activator inhibitor‐1 and RGD peptides M Germer, SM Kanse, T Kirkegaard, L Kjøller, B Felding‐Habermann, ... European journal of biochemistry 253 (3), 669-674, 1998 | 63 | 1998 |
| A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells S Thrane, AM Pedersen, MBH Thomsen, T Kirkegaard, BB Rasmussen, ... Oncogene 34 (32), 4199-4210, 2015 | 59 | 2015 |
| Bad expression predicts outcome in patients treated with tamoxifen E Cannings, T Kirkegaard, SM Tovey, B Dunne, TG Cooke, JMS Bartlett Breast cancer research and treatment 102, 173-179, 2007 | 58 | 2007 |
| Bad expression predicts outcome in patients treated with tamoxifen E Cannings, T Kirkegaard, SM Tovey, B Dunne, TG Cooke, JMS Bartlett Breast cancer research and treatment 102, 173-179, 2007 | 58 | 2007 |
